Related references
Note: Only part of the references are listed.PTRF-Cavin, a conserved cytoplasmic protein required for Caveola formation and function
Michelle M. Hill et al.
CELL (2008)
Quantitative proteomics using stable isotope labeling with amino acids in cell culture
H. C. Harsha et al.
NATURE PROTOCOLS (2008)
Signaling networks assembled by oncogenic EGFR and c-Met
Ailan Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization
Libin Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Paul H. Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity
Dexing Fang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Evidence that MIG-6 is a tumor-suppressor gene
Y-W Zhang et al.
ONCOGENE (2007)
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks
Jesper V. Olsen et al.
CELL (2006)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
Phosphoproteomic analysis of Her2/neu signaling and inhibition
Ron Bose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Katerina Politi et al.
GENES & DEVELOPMENT (2006)
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji et al.
CANCER CELL (2006)
Multiple oncogenic changes (K-RASV12, p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells
M Sato et al.
CANCER RESEARCH (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
Alejandro Wolf-Yadlin et al.
MOLECULAR SYSTEMS BIOLOGY (2006)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
JR Jiang et al.
CANCER RESEARCH (2005)
Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules
Y Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation
I Kratchmarova et al.
SCIENCE (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics
B Blagoev et al.
NATURE BIOTECHNOLOGY (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins
RD Ramirez et al.
CANCER RESEARCH (2004)
Advances to Bayesian network inference for generating causal networks from observational biological data
J Yu et al.
BIOINFORMATICS (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes
N Aboulaich et al.
BIOCHEMICAL JOURNAL (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling
B Blagoev et al.
NATURE BIOTECHNOLOGY (2003)
ErbB-β-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu Transgenic carcinomas
JA Schroeder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
